Valli De Re1, Maria Lina Tornesello2, Mariangela De Zorzi1, Laura Caggiari1, Francesca Pezzuto2, Patrizia Leone3, Vito Racanelli3, Gianfranco Lauletta3, Stefania Zanussi1, Ombretta Repetto1, Laura Gragnani4, Francesca Maria Rossi5, Riccardo Dolcetti6, Anna Linda Zignego4, Franco M Buonaguro2, Agostino Steffan1. 1. Immunopathology and Cancer Biomarkers/Bioproteomic facility, Department of Translational Research, Centro di Riferimento Oncologico (CRO) IRCCS, Cancer Institute, Aviano, Italy. 2. Molecular biology, viral oncology Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli, Italy. 3. Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy. 4. Center for Systemic Manifestations of Hepatitis Viruses (MaSVE), Internal Medicine and Liver Unit, Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy, Florence, Italy. 5. Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico (CRO) IRCCS, Aviano (PN), Italy. 6. The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Abstract
BACKGROUND: Genetic variants of IFNL4 and PDCD1 genes have been shown to influence the spontaneous clearance of hepatitis C virus (HCV) infection. We investigated the IFNL4 rs12979860 and the PDCD1 polymorphisms in 734 HCV-positive patients, including 461 cases with liver disease of varying severity and 273 patients with lymphoproliferative disorders to determine the association of these genes with patient's outcome. METHODS: Expression levels of PDCD1 mRNA encoded by haplotypes were investigated by quantitative PCR in hepatocellular carcinoma (HCC) tissue and peripheral blood mononuclear cells. Flow cytometry was used to detect PD-1 and its ligand PD-L1. RESULTS: The frequency of IFNL4 rs12979860 C/T or T/T genotypes was significantly higher in patients with HCV-related diseases than blood donors (P < .0001). Patients expressing the IFNλ4 variant with one amino acid change that reduces IFNλ4 secretion was found increased in frequency in HCV-related diseases compared to HCC PDCD1 mRNA levels in HCC tissue were significantly higher in cases carrying the PD-1.3 A or the PD-1.7 G allele (P = .0025 and P = .0167). Linkage disequilibrium (LD) between PD-1.3 and IFNL4 was found in patients with mixed cryoglobulinaemia (MC) only (LD = 0 in HCC; LD = 72 in MC). PBMCs of MC patients expressed low levels of PD-L1 in CD19+IgM+B cells and of PD-1 in CD4+T cells suggesting the involvement of regulatory B cell-T cell interaction to the pathogenesis of MC. CONCLUSION: Collectively, our data indicate an important contribution of IFNλ4 expression to the development of HCV-related HCC and an epistatic contribution of IFNL4 and PDCD1 in MC. LAY SUMMARY: Studies of IFNL4 and PDCD1 genes are helpful to better understand the role of host genetic factors and immune antigens influencing the outcome of HCV-related diseases. Our data support an association between the expression of IFNλ4, which prevents the expression of IFNλ3, with all the different HCV-related diseases studied, and besides, evidence that a higher IFNλ4 expression is associated with hepatocellular at a younger age. The expression pattern of low PD-L1 on B cells and high PD-1 on CD4+T-cells in patients with HCV-positive cryoglobulinaemia suggests a critical role of the PD-1/PD-L1 signaling in modulating B cell-T cell interaction in this lymphoproliferative disease.
BACKGROUND: Genetic variants of IFNL4 and PDCD1 genes have been shown to influence the spontaneous clearance of hepatitis C virus (HCV) infection. We investigated the IFNL4 rs12979860 and the PDCD1 polymorphisms in 734 HCV-positive patients, including 461 cases with liver disease of varying severity and 273 patients with lymphoproliferative disorders to determine the association of these genes with patient's outcome. METHODS: Expression levels of PDCD1 mRNA encoded by haplotypes were investigated by quantitative PCR in hepatocellular carcinoma (HCC) tissue and peripheral blood mononuclear cells. Flow cytometry was used to detect PD-1 and its ligand PD-L1. RESULTS: The frequency of IFNL4 rs12979860 C/T or T/T genotypes was significantly higher in patients with HCV-related diseases than blood donors (P < .0001). Patients expressing the IFNλ4 variant with one amino acid change that reduces IFNλ4 secretion was found increased in frequency in HCV-related diseases compared to HCC PDCD1 mRNA levels in HCC tissue were significantly higher in cases carrying the PD-1.3 A or the PD-1.7 G allele (P = .0025 and P = .0167). Linkage disequilibrium (LD) between PD-1.3 and IFNL4 was found in patients with mixed cryoglobulinaemia (MC) only (LD = 0 in HCC; LD = 72 in MC). PBMCs of MC patients expressed low levels of PD-L1 in CD19+IgM+B cells and of PD-1 in CD4+T cells suggesting the involvement of regulatory B cell-T cell interaction to the pathogenesis of MC. CONCLUSION: Collectively, our data indicate an important contribution of IFNλ4 expression to the development of HCV-related HCC and an epistatic contribution of IFNL4 and PDCD1 in MC. LAY SUMMARY: Studies of IFNL4 and PDCD1 genes are helpful to better understand the role of host genetic factors and immune antigens influencing the outcome of HCV-related diseases. Our data support an association between the expression of IFNλ4, which prevents the expression of IFNλ3, with all the different HCV-related diseases studied, and besides, evidence that a higher IFNλ4 expression is associated with hepatocellular at a younger age. The expression pattern of low PD-L1 on B cells and high PD-1 on CD4+T-cells in patients with HCV-positive cryoglobulinaemia suggests a critical role of the PD-1/PD-L1 signaling in modulating B cell-T cell interaction in this lymphoproliferative disease.
Authors: Wen Xiao; Long Feng Jiang; Xiao Zhao Deng; Dan Yan Zhu; Jia Ping Pei; Mao Lei Xu; Bing Jun Li; Chang Jun Wang; Jing Hai Zhang; Qi Zhang; Zhen Xian Zhou; Wei Liang Ding; Xiao Dong Xu; Ming Yue Journal: Immunol Res Date: 2016-04 Impact factor: 2.829
Authors: V De Re; S De Vita; A Marzotto; M Rupolo; A Gloghini; B Pivetta; D Gasparotto; A Carbone; M Boiocchi Journal: Blood Date: 2000-11-15 Impact factor: 22.113
Authors: Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed Journal: Nature Date: 2005-12-28 Impact factor: 49.962
Authors: Valli De Re; Maria Lina Tornesello; Mariangela De Zorzi; Laura Caggiari; Francesca Pezzuto; Patrizia Leone; Vito Racanelli; Gianfranco Lauletta; Stefania Zanussi; Ombretta Repetto; Laura Gragnani; Francesca Maria Rossi; Riccardo Dolcetti; Anna Linda Zignego; Franco M Buonaguro; Agostino Steffan Journal: Liver Int Date: 2021-01 Impact factor: 5.828